Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

Inclusion Criteria:

- Type of subject: Outpatient

- Informed consent: Subjects must give their signed and dated written informed consent
to participate

- Gender: Male subjects or female subjects. Female subjects must be post-menopausal or
using a highly effective method for avoidance of pregnancy. The decision to include or
exclude women of childbearing potential may be made at the discretion of the
investigator in accordance with local practice in relation to adequate contraception.

- Age: >=40 years of age at Screening (Visit 1)

- COPD diagnosis: Subjects with a clinical history of COPD in accordance with the
definition by the American Thoracic Society/European Respiratory Society: COPD is a
preventable and treatable disease characterized by airflow limitation that is not
fully reversible. The airflow limitation is usually progressive and is associated with
an abnormal inflammatory response of the lungs to noxious particles or gases,
primarily caused by cigarette smoking. Although COPD affects the lungs, it is also
associated with significant systemic consequences.

- Severity of disease: Subjects with a measured post-albuterol (salbutamol) FEV1/ Forced
Vital Capacity (FVC) ratio of <=0.70 and FEV1 >=30 to <=70 percent of predicted normal
values using Global Lung Function Initiative 2012 reference equations at Screening
(Visit 1).

- Tobacco use: Subjects with a current or prior history of >=10 pack-years of cigarette
smoking at Screening (Visit 1). Former smokers are defined as those who have stopped
smoking for at least 6 months prior to Visit 1.

- History of COPD exacerbation: A documented history (e.g., medical record verification)
of at least one COPD exacerbation in the 12 months prior to Screening (Visit 1) that
required either systemic/oral corticosteroids, antibiotics and/or hospitalization.

- Current symptoms of COPD: A Subject Diary combined symptom score (combination of
breathlessness, cough, sputum, and night time awakenings requiring treatment with
albuterol [salbutamol]) of >=4 on at least 5 of the 7 days immediately preceding Visit
2 (Randomization)

- QTc Criteria: QTc <450 msec or QTc <480 msec for patients with bundle branch block.

Exclusion Criteria:

- Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant
during the study.

- Asthma: Subjects with a current diagnosis of asthma. (Subjects with a prior history of
asthma are eligible if they have a current diagnosis of COPD).

- Other respiratory disorders: Subjects with alpha1-antitrypsin deficiency as the
underlying cause of COPD as the underlying cause of COPD, active tuberculosis, lung
cancer, bronchiectasis (Note: focal bronchiectasis is not exclusionary), sarcoidosis,
pulmonary fibrosis (Note: focal fibrotic pulmonary lesions are not exclusionary),
primary pulmonary hypertension, interstitial lung diseases, or other active pulmonary
diseases.

- Lung resection: Subjects with lung volume reduction surgery within the 12 months prior
to Screening (Visit 1).

- Chest X-ray (or computed tomography [CT] scan): Subjects with a chest X-ray (or CT
scan) that reveals evidence of clinically significant abnormalities not believed to be
due to the presence of COPD. A chest X-ray must be taken at Screening (Visit 1) if a
chest X-ray or CT scan is not available within 1 year prior to Screening (Visit 1).

- Hospitalization: Subjects who are hospitalized due to poorly controlled COPD that has
not resolved at least 4 weeks prior to Screening (Visit 1) and at least 6 weeks
following the last dose of systemic corticosteroids.

- Poorly controlled COPD: Subjects with poorly controlled COPD, defined as the
occurrence of any of the following in the 6 weeks prior to Screening (Visit 1): Acute
worsening of COPD that is managed by subject with systemic corticosteroids or
antibiotics or that requires treatment prescribed by a physician.

- Lower respiratory tract infection: Subjects with lower respiratory tract infection
that required the use of antibiotics within 6 weeks prior to Screening (Visit 1).

- COPD exacerbation/lower respiratory tract infection during the Run-In Period: Subjects
who experience a moderate/severe COPD exacerbation (As per definition of "COPD
Exacerbations and Pneumonia" in protocol) and/or a lower respiratory tract infection
(including pneumonia) during the Run-In Period.

- Abnormal, clinically significant laboratory finding: Subjects who have an abnormal
clinical significant finding in any liver chemistry test at Screening (Visit 1) or
upon repeat prior to randomization.

- Abnormal, clinically significant 12-lead ECG at Screening (Visit 1): Subjects who have
an abnormal, clinically significant 12-Lead electrocardiogram (ECG) finding at
Screening (Visit 1) or upon repeat prior to randomization.

- Other diseases/abnormalities: Subjects with historical or current evidence of
clinically significant and unstable disease such as cardiovascular (e.g., patients
requiring implantable cardioverter-defibrillators (ICD), pacemaker requiring a rate
set >60 beats per minute (bpm), uncontrolled hypertension, New Your Heart Association
Class IV, known left ventricular ejection fraction <30 percent) neurological,
psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes
or thyroid disease), peptic ulcer disease, or hematological abnormalities.

- Liver disease: Subjects who have unstable liver disease (as defined by the presence of
ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric
varices or persistent jaundice), cirrhosis, known biliary abnormalities (with the
exception of Gilbert's syndrome or asymptomatic gallstones). Note: Subjects with
chronic stable hepatitis B and C are eligible if the subject otherwise meets entry
criteria (e.g., presence of hepatitis B surface antigen or positive hepatitis C test
result within 3 months of screening). However, subjects with chronic stable hepatitis
B are excluded if significant immunosuppressive or cytotoxic agents are administered,
due to risk of hepatitis B reactivation, unless the hepatitis B antivirals are
administered as outlined in the Chronic Hepatitis B American Association for the Study
of Liver Diseases' (AASLD) Practice Guidelines.

- Cancer: Subjects with carcinoma that has not been in complete remission for at least 5
years. Carcinoma in situ of the cervix, squamous cell carcinoma and basal cell
carcinoma of the skin would not be excluded if the subject has been considered cured
within 5 years since diagnosis.

- Contraindications: Subjects with a history of allergy or hypersensitivity to any of
the study medications (e.g. beta-agonists, corticosteroids) or components of the
inhalation powder (e.g., lactose, magnesium stearate). In addition, subjects with a
history of severe milk protein allergy that, in the opinion of the investigator,
contraindicates the subject's participation will also be excluded.

- Drug/alcohol abuse: Subjects with a known or suspected history of alcohol or drug
abuse within the last 2 years

- Medication prior to spirometry: Subjects who are medically unable to withhold their
albuterol (salbutamol) or their ipratropium bromide for the 4-hour period required
prior to spirometry testing at each study visit.

- Additional medication: Use of certain medications such as bronchodilators and
corticosteroids for the protocol-specific times prior to Visit 1 (the Investigator
will discuss the specific medications)"

- Oxygen therapy: Subjects receiving treatment with long-term oxygen therapy (LTOT) or
nocturnal oxygen therapy required for greater than 12 hours a day. Oxygen as needed
(prn) use (i.e., <=12 hours per day) is not exclusionary.

- Sleep apnea: Subjects with clinically significant sleep apnea who require use of
continuous positive airway pressure (CPAP) device or non-invasive positive pressure
ventilation (NIPPV).

- Pulmonary rehabilitation: Subjects who have participated in the acute phase of a
Pulmonary Rehabilitation Program within 4 weeks prior to Screening (Visit 1) or who
will enter the acute phase of a Pulmonary Rehabilitation Program during the study.
Subjects who are in the maintenance phase of a Pulmonary Rehabilitation Program are
not excluded.

- Non-Compliance during Run-In Period: Failure to demonstrate adequate compliance
defined as completion of Diary Card (completed all diary entries on at least 5 of the
last 7 consecutive days), the ability to withhold anti-COPD medications and to keep
clinic visit appointments. In addition, subjects must have recorded the Run-In study
medication use on at least 5 of the last 7, consecutive days of the Run-In period to
continue in the study.

- Potential of non-compliance: Subjects at risk of non-compliance, or unable to comply
with the study procedures. Any infirmity, disability, or geographic location that
would limit compliance for scheduled visits.

- Questionable validity of consent: Subjects with a history of psychiatric disease,
intellectual deficiency, poor motivation or other conditions that will limit the
validity of informed consent to participate in the study.

- Prior use of study medication/other investigational drugs: Subjects who have received
an investigational drug within 30 days of entry into this study (Screening), or within
5 drug half-lives of the investigational drug, whichever is longer. Note: Subjects who
participated in a previously completed study and/or were excluded/ withdrawn from an
ongoing study that included/includes FF/VI and/or VI are eligible to participate in
the current study, if they have not received investigational study medication within
30 days of Screening (Visit 1).

- Affiliation with investigator site: Study investigators, sub-investigators, study
coordinators, employees of a participating investigator or immediate family members of
the aforementioned are excluded from participating in this study.